S&P 500   3,386.15 (+0.47%)
DOW   29,348.03 (+0.40%)
QQQ   236.98 (+0.96%)
AAPL   323.62 (+1.45%)
FB   217.49 (-0.14%)
MSFT   187.28 (+0.03%)
GOOGL   1,524.87 (+0.36%)
AMZN   2,170.22 (+0.67%)
CGC   21.77 (-0.77%)
NVDA   314.70 (+6.11%)
BABA   222.14 (+0.73%)
MU   59.99 (+3.88%)
GE   12.61 (-1.10%)
TSLA   917.42 (+6.88%)
AMD   58.90 (+3.53%)
T   38.44 (+0.47%)
ACB   1.71 (+4.27%)
F   8.00 (-0.74%)
NFLX   386.19 (-0.41%)
PRI   135.69 (+0.05%)
BAC   34.72 (+1.31%)
DIS   141.30 (+1.55%)
GILD   67.35 (+0.51%)
S&P 500   3,386.15 (+0.47%)
DOW   29,348.03 (+0.40%)
QQQ   236.98 (+0.96%)
AAPL   323.62 (+1.45%)
FB   217.49 (-0.14%)
MSFT   187.28 (+0.03%)
GOOGL   1,524.87 (+0.36%)
AMZN   2,170.22 (+0.67%)
CGC   21.77 (-0.77%)
NVDA   314.70 (+6.11%)
BABA   222.14 (+0.73%)
MU   59.99 (+3.88%)
GE   12.61 (-1.10%)
TSLA   917.42 (+6.88%)
AMD   58.90 (+3.53%)
T   38.44 (+0.47%)
ACB   1.71 (+4.27%)
F   8.00 (-0.74%)
NFLX   386.19 (-0.41%)
PRI   135.69 (+0.05%)
BAC   34.72 (+1.31%)
DIS   141.30 (+1.55%)
GILD   67.35 (+0.51%)
S&P 500   3,386.15 (+0.47%)
DOW   29,348.03 (+0.40%)
QQQ   236.98 (+0.96%)
AAPL   323.62 (+1.45%)
FB   217.49 (-0.14%)
MSFT   187.28 (+0.03%)
GOOGL   1,524.87 (+0.36%)
AMZN   2,170.22 (+0.67%)
CGC   21.77 (-0.77%)
NVDA   314.70 (+6.11%)
BABA   222.14 (+0.73%)
MU   59.99 (+3.88%)
GE   12.61 (-1.10%)
TSLA   917.42 (+6.88%)
AMD   58.90 (+3.53%)
T   38.44 (+0.47%)
ACB   1.71 (+4.27%)
F   8.00 (-0.74%)
NFLX   386.19 (-0.41%)
PRI   135.69 (+0.05%)
BAC   34.72 (+1.31%)
DIS   141.30 (+1.55%)
GILD   67.35 (+0.51%)
S&P 500   3,386.15 (+0.47%)
DOW   29,348.03 (+0.40%)
QQQ   236.98 (+0.96%)
AAPL   323.62 (+1.45%)
FB   217.49 (-0.14%)
MSFT   187.28 (+0.03%)
GOOGL   1,524.87 (+0.36%)
AMZN   2,170.22 (+0.67%)
CGC   21.77 (-0.77%)
NVDA   314.70 (+6.11%)
BABA   222.14 (+0.73%)
MU   59.99 (+3.88%)
GE   12.61 (-1.10%)
TSLA   917.42 (+6.88%)
AMD   58.90 (+3.53%)
T   38.44 (+0.47%)
ACB   1.71 (+4.27%)
F   8.00 (-0.74%)
NFLX   386.19 (-0.41%)
PRI   135.69 (+0.05%)
BAC   34.72 (+1.31%)
DIS   141.30 (+1.55%)
GILD   67.35 (+0.51%)
Log in

Aptevo Therapeutics News Headlines (NASDAQ:APVO)

$0.49
-0.01 (-2.00 %)
(As of 02/19/2020 04:00 PM ET)
Today's Range
$0.47
Now: $0.49
$0.51
50-Day Range
$0.48
MA: $0.60
$0.70
52-Week Range
$0.44
Now: $0.49
$1.73
Volume385,807 shs
Average Volume470,573 shs
Market Capitalization$22.20 million
P/E RatioN/A
Dividend YieldN/A
Beta2.51

Headlines

Aptevo Therapeutics (NASDAQ APVO) News Headlines

Source:
DateHeadline
Short Interest in Aptevo Therapeutics Inc (NASDAQ:APVO) Declines By 10.7%Short Interest in Aptevo Therapeutics Inc (NASDAQ:APVO) Declines By 10.7%
www.americanbankingnews.com - February 14 at 5:23 PM
Aptevo Therapeutics Inc. Common Stock (APVO) Insider ActivityAptevo Therapeutics Inc. Common Stock (APVO) Insider Activity
www.nasdaq.com - February 14 at 12:41 AM
Contrasting Sernova (OTCMKTS:SEOVF) & Aptevo Therapeutics (OTCMKTS:APVO)Contrasting Sernova (OTCMKTS:SEOVF) & Aptevo Therapeutics (OTCMKTS:APVO)
www.americanbankingnews.com - February 13 at 6:47 PM
Aptevo Therapeutics Inc. Common Stock (APVO) Revenue EPSAptevo Therapeutics Inc. Common Stock (APVO) Revenue EPS
www.nasdaq.com - February 12 at 5:20 PM
Aptevo Therapeutics Inc. Common Stock (APVO) Dividend HistoryAptevo Therapeutics Inc. Common Stock (APVO) Dividend History
www.nasdaq.com - February 12 at 5:20 PM
 Aptevo Therapeutics Inc (NASDAQ:APVO) Given Consensus Recommendation of "Strong Buy" by Analysts Aptevo Therapeutics Inc (NASDAQ:APVO) Given Consensus Recommendation of "Strong Buy" by Analysts
www.americanbankingnews.com - February 2 at 12:31 PM
Aptevo Therapeutics Doses First Patient in IXINITY Clinical Trial for Potential Pediatric Label ExpansionAptevo Therapeutics Doses First Patient in IXINITY Clinical Trial for Potential Pediatric Label Expansion
finance.yahoo.com - January 30 at 11:49 AM
Aptevo Therapeutics Inc. (APVO): Are Hedge Funds Right About This Stock?Aptevo Therapeutics Inc. (APVO): Are Hedge Funds Right About This Stock?
finance.yahoo.com - December 19 at 6:51 PM
Aptevo Therapeutics Receives Orphan Drug Designation for APVO436 for the Treatment of Acute Myelogenous LeukemiaAptevo Therapeutics Receives Orphan Drug Designation for APVO436 for the Treatment of Acute Myelogenous Leukemia
finance.yahoo.com - December 6 at 1:23 PM
Alligator Bioscience AB Appoints Chief Operating OfficerAlligator Bioscience AB Appoints Chief Operating Officer
www.prnewswire.com - November 29 at 3:28 AM
What Makes Aptevo Therapeutics Inc. (APVO) a New Buy StockWhat Makes Aptevo Therapeutics Inc. (APVO) a New Buy Stock
finance.yahoo.com - November 12 at 12:31 PM
Aptevo Therapeutics EPS beats by $0.01, beats on revenueAptevo Therapeutics EPS beats by $0.01, beats on revenue
seekingalpha.com - November 7 at 12:55 PM
Aptevo Therapeutics Reports Third Quarter 2019 Financial ResultsAptevo Therapeutics Reports Third Quarter 2019 Financial Results
finance.yahoo.com - November 7 at 12:55 PM
Aptevo Therapeutics: Profitability Might Be 12 Months AwayAptevo Therapeutics: Profitability Might Be 12 Months Away
seekingalpha.com - October 8 at 2:04 PM
BRIEF-Aptevo Therapeutics Reports Decision To Discontinue Development Of APVO210BRIEF-Aptevo Therapeutics Reports Decision To Discontinue Development Of APVO210
www.msn.com - October 3 at 9:40 PM
Aptevo Therapeutics Provides Corporate and Pipeline UpdateAptevo Therapeutics Provides Corporate and Pipeline Update
finance.yahoo.com - October 3 at 4:34 PM
Aptevo Therapeutics Introduces New Adaptir™ Bispecific Antibody Candidate Intended for the Treatment of Solid TumorsAptevo Therapeutics Introduces New Adaptir™ Bispecific Antibody Candidate Intended for the Treatment of Solid Tumors
finance.yahoo.com - September 19 at 1:45 PM
Aptevo Therapeutics: IXINITY Revenue Still The FocusAptevo Therapeutics: IXINITY Revenue Still The Focus
seekingalpha.com - August 22 at 6:20 PM
Aptevo Therapeutics Reports Second Quarter 2019 Financial ResultsAptevo Therapeutics Reports Second Quarter 2019 Financial Results
finance.yahoo.com - August 9 at 9:18 AM
Aptevo Therapeutics Receives $4.3 Million Milestone Payment From Saol International LimitedAptevo Therapeutics Receives $4.3 Million Milestone Payment From Saol International Limited
finance.yahoo.com - August 7 at 10:46 AM
Buy Aptevo Therapeutics Before Their Q2 ResultsBuy Aptevo Therapeutics Before Their Q2 Results
seekingalpha.com - July 30 at 9:34 AM
BRIEF-Aptevo Therapeutics Reports Continued Progress In Apvo210 And Apvo436 Clinical TrialsBRIEF-Aptevo Therapeutics Reports Continued Progress In Apvo210 And Apvo436 Clinical Trials
www.msn.com - July 25 at 9:50 PM
Aptevo Therapeutics Reports Continued Progress In APVO210 and APVO436 Clinical TrialsAptevo Therapeutics Reports Continued Progress In APVO210 and APVO436 Clinical Trials
finance.yahoo.com - July 25 at 4:48 PM
Friday 7/12 Insider Buying Report: PBHC, APVOFriday 7/12 Insider Buying Report: PBHC, APVO
www.nasdaq.com - July 13 at 11:18 AM
Aptevo Announces Pricing of $22 Million Offering of Common Stock and WarrantsAptevo Announces Pricing of $22 Million Offering of Common Stock and Warrants
www.globenewswire.com - July 4 at 5:20 PM
Aptevo Therapeutics Launches New 3000 IU IXINITY Assay Offering Enhanced User Experience and Improved Convenience for Hemophilia B PatientsAptevo Therapeutics Launches New 3000 IU IXINITY Assay Offering Enhanced User Experience and Improved Convenience for Hemophilia B Patients
finance.yahoo.com - June 25 at 9:55 AM
Aptevo Therapeutics EPS in-line, beats on revenueAptevo Therapeutics EPS in-line, beats on revenue
seekingalpha.com - May 9 at 6:05 PM
Aptevo Therapeutics Reports First Quarter 2019 Financial ResultsAptevo Therapeutics Reports First Quarter 2019 Financial Results
www.globenewswire.com - May 9 at 9:48 AM
Aptevo Therapeutics Reports IXINITY® and Pipeline ProgressAptevo Therapeutics Reports IXINITY® and Pipeline Progress
finance.yahoo.com - April 15 at 10:42 AM
What Kind Of Investor Owns Most Of Aptevo Therapeutics Inc. (NASDAQ:APVO)?What Kind Of Investor Owns Most Of Aptevo Therapeutics Inc. (NASDAQ:APVO)?
finance.yahoo.com - April 11 at 6:02 PM
Aptevo Therapeutics Presents New Preclinical Data for APVO436 and ALG.APV-527 at the American Association for Cancer Research 2019 Annual MeetingAptevo Therapeutics Presents New Preclinical Data for APVO436 and ALG.APV-527 at the American Association for Cancer Research 2019 Annual Meeting
finance.yahoo.com - April 2 at 12:27 PM
Aptevo Therapeutics to Present New Preclinical Data for APVO436 and ALG.APV.527 at the American Association for Cancer Research 2019 Annual MeetingAptevo Therapeutics to Present New Preclinical Data for APVO436 and ALG.APV.527 at the American Association for Cancer Research 2019 Annual Meeting
finance.yahoo.com - March 25 at 9:35 AM
Aptevo Therapeutics begins phase 1 trial of APVO210; shares up 11% premarketAptevo Therapeutics begins phase 1 trial of APVO210; shares up 11% premarket
seekingalpha.com - March 20 at 6:12 PM
Form SC 13G Aptevo Therapeutics Inc. Filed by: Stonepine Capital Management, LLC - StreetInsider.comForm SC 13G Aptevo Therapeutics Inc. Filed by: Stonepine Capital Management, LLC - StreetInsider.com
www.streetinsider.com - March 20 at 9:31 AM
Form 8-K Aptevo Therapeutics Inc. For: Mar 18 - StreetInsider.comForm 8-K Aptevo Therapeutics Inc. For: Mar 18 - StreetInsider.com
www.streetinsider.com - March 20 at 9:31 AM
Aptevo Therapeutics (APVO) Commences Phase 1 Clinical Trial of APVO210 for the Treatment of Autoimmune and Inflammatory Diseases - StreetInsider.comAptevo Therapeutics (APVO) Commences Phase 1 Clinical Trial of APVO210 for the Treatment of Autoimmune and Inflammatory Diseases - StreetInsider.com
www.streetinsider.com - March 20 at 9:31 AM
Aptevo Therapeutics Begins Phase 1 Clinical Trial of APVO210 a Novel Bispecific Antibody for the Treatment of Autoimmune and Inflammatory Diseases - GlobeNewswireAptevo Therapeutics Begins Phase 1 Clinical Trial of APVO210 a Novel Bispecific Antibody for the Treatment of Autoimmune and Inflammatory Diseases - GlobeNewswire
www.globenewswire.com - March 20 at 9:31 AM
Aptevo Therapeutics Begins Phase 1 Clinical Trial of APVO210 a Novel Bispecific Antibody for the Treatment of Autoimmune and Inflammatory DiseasesAptevo Therapeutics Begins Phase 1 Clinical Trial of APVO210 a Novel Bispecific Antibody for the Treatment of Autoimmune and Inflammatory Diseases
finance.yahoo.com - March 20 at 9:31 AM
Aptevo Therapeutics Reports 2018 Financial Results and Provides Business Update - GlobeNewswireAptevo Therapeutics Reports 2018 Financial Results and Provides Business Update - GlobeNewswire
globenewswire.com - March 18 at 6:13 PM
Aptevo Therapeutics Reports 2018 Financial Results and Provides Business UpdateAptevo Therapeutics Reports 2018 Financial Results and Provides Business Update
www.globenewswire.com - March 18 at 9:32 AM
Aptevo Therapeutics Reports 2018 Financial Results and Provides Business UpdateAptevo Therapeutics Reports 2018 Financial Results and Provides Business Update
finance.yahoo.com - March 18 at 9:32 AM
Aptevo Therapeutics Inc. (APVO) Moves to Buy: Rationale Behind the UpgradeAptevo Therapeutics Inc. (APVO) Moves to Buy: Rationale Behind the Upgrade
finance.yahoo.com - March 14 at 5:59 PM
Aptevo Therapeutics Inc. (APVO)Aptevo Therapeutics Inc. (APVO)
finance.yahoo.com - March 11 at 10:39 AM
Aptevo down 45% on pricing of equity offeringAptevo down 45% on pricing of equity offering
seekingalpha.com - March 7 at 10:35 AM
Aptevo Announces Proposed Public Offering of Common Stock and WarrantsAptevo Announces Proposed Public Offering of Common Stock and Warrants
finance.yahoo.com - March 6 at 6:02 PM
Aptevo Therapeutics +5.3% after projecting cut in cash burnAptevo Therapeutics +5.3% after projecting cut in cash burn
seekingalpha.com - January 7 at 5:11 PM
Aptevo Therapeutics Highlights Key 2019 PrioritiesAptevo Therapeutics Highlights Key 2019 Priorities
finance.yahoo.com - January 7 at 9:33 AM
Aptevo Therapeutics Collects $3.3 Million In Escrow Funds From Saol TherapeuticsAptevo Therapeutics Collects $3.3 Million In Escrow Funds From Saol Therapeutics
finance.yahoo.com - January 3 at 9:51 AM
Aptevo Therapeutics Announces Up To $35 Million Common Stock Purchase Agreement With Lincoln Park CapitalAptevo Therapeutics Announces Up To $35 Million Common Stock Purchase Agreement With Lincoln Park Capital
finance.yahoo.com - December 21 at 9:33 AM
Need To Know: Aptevo Therapeutics Inc. (NASDAQ:APVO) Insiders Have Been Buying SharesNeed To Know: Aptevo Therapeutics Inc. (NASDAQ:APVO) Insiders Have Been Buying Shares
finance.yahoo.com - December 20 at 4:36 PM
This page was last updated on 2/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel